Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  BioAlliance Pharma SA    C4X   

 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials (€)
Sales 2016 3,45 M
EBIT 2016 -23,6 M
Net income 2016 -23,2 M
Finance 2016 7,29 M
Yield 2016 -
Sales 2017 10,4 M
EBIT 2017 -17,3 M
Net income 2017 -17,1 M
Finance 2017 0,75 M
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales2016 32,5x
EV / Sales2017 11,4x
Capitalization 119 M
More Financials
Company
Onxeo SA is a biotechnology company, which engages in the development of drugs for the treatment of orphan diseases.It produces and develops ophan oncology products under the brand names Livatag, Validive, Beleodaq, and AsiDNA.The company was founded by Gilles Avenard and Dominique Costantini on... 
Sector
Pharmaceuticals
Calendar
03/07Earnings Release
More about the company
Surperformance© ratings of BioAlliance Pharma SA
Trading Rating : Investor Rating :
More Ratings
Latest news on BIOALLIANCE PHARMA SA
02/17 ONXEO : Drugs for Herpes Labialis Market 2017 - GSK, Novartis, Teva, Apotex, Cad..
02/13 ONXEO : receives USPTO Notice of Allowance for a new AsiDNA™-related paten..
02/08 ONXEO : Information on ReLive Trial Design and Role of its Data Safety and Monit..
01/06 EQS-NEWS : Edison issues outlook on Onxeo (ONXEO)
2016 ONXEO : to Attend Two French Investor Conferences in January
2016 ONXEO : Strengthens AsiDNA Patent Protection in Europe
2016 ONXEO : to Participate in the Guggenheim Securities 4th Annual Boston Healthcare..
2016 ONXEO COLLABORATES WITH THE ROYAL CO : Onxeo samarbejder med Royal College of Su..
2016 ONXEO : Receives USPTO Notice of Allowance for Key AsiDNATM Patent, Extending IP..
2016 ONXEO RECEIVES USPTO NOTICE OF ALLOW : Onxeo modtager “Notice of Allowance..
More news
Sector news : Pharmaceuticals - NEC
08:06aDJSANOFI : Lonza to Invest CHF290 Million in New Plant in Switzerland
02/24DJSHIRE : Files 8K - Other Events
02/24DJASTRAZENECA : Hyperkalaemia Drug Clears Scientific Hurdle for European Approval
02/24DJASTRAZENECA : Gets Approval for Drug Treating Hyperkalaemia
02/24 Exclusive - Trump says Republican border tax could boost U.S. jobs
More sector news : Pharmaceuticals - NEC
Advertisement
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 1
Average target price 8,10 €
Spread / Average Target 219%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Judith Greciet Chief Executive Officer & Director
Joseph S. Zakrzewski Non-Executive Chairman
Nicolas Fellmann Chief Financial Officer & Secretary
Graham K. Dixon Chief Scientific Officer
David Horn Solomon Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BIOALLIANCE PHARMA SA126
JOHNSON & JOHNSON6.53%333 891
ROCHE HOLDING LTD.5.42%210 192
PFIZER INC.5.48%207 902
NOVARTIS AG4.72%202 648
MERCK & CO., INC.12.38%182 412
More Results